Loading
A phase 3 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma is a phase 3 interventional study registered as NCT04712643 by Hoffmann-La Roche, with 342 participants enrolled, started 2021-03-12 and due to reach its primary completion in 2029-02-01. Interventions recorded: Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE). Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Atezolizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Roche / Genentech, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Atezolizumab, Bevacizumab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Roche / Genentech, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Atezolizumab, Bevacizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/